ASCO 2020 HCC In Depth

ASCO 2020 HCC In-Depth

Study to Evaluate Synergy of 3-Drug Combo in HCC, Liver-Dominant Cancers

A trial in progress will evaluate the combination of immunotherapy with tadalafil and vancomycin.

Lenvatinib, Pembrolizumab Combination Promising in Unresectable HCC

The phase 1b included 104 patients who received lenvatinib 12 mg per day or 8 mg per day plus pembrolizumab 200 mg on day 1 of a 21-day cycle.

Circulating Tumor DNA Levels Linked with Tumor Burden, Survival in HCC

Noninvasive method could help monitor treatment responses.

Comparing Stereotactic Body Radiation Therapy With Transarterial Chemoembolization in Early-Stage HCC

SBRT preserved quality of life and eliminated need for post-TACE hospitalization in patients with hepatocellular carcinoma.

Apatinib Significantly Improved Survival in Chinese Patients with Advanced HCC

The administration of apatinib in patients with advanced HCC led to improvements in survival with a manageable safety profile.

Intrahepatic T-VEC Injection Plus Pembrolizumab Feasible in HCC, Liver Metastases

Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.